Danaher Co. (DHR) Holdings Increased by Parametric Portfolio Associates LLC
Parametric Portfolio Associates LLC boosted its position in Danaher Co. (NYSE:DHR) by 6.2% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,612,412 shares of the conglomerate’s stock after acquiring an additional 94,344 shares during the period. Parametric Portfolio Associates LLC owned about 0.23% of Danaher worth $138,313,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of Danaher by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 41,488,407 shares of the conglomerate’s stock valued at $3,501,206,000 after buying an additional 520,776 shares during the period. BlackRock Inc. grew its stake in shares of Danaher by 3.2% during the 2nd quarter. BlackRock Inc. now owns 39,201,798 shares of the conglomerate’s stock valued at $3,308,239,000 after buying an additional 1,233,876 shares during the period. FMR LLC grew its stake in shares of Danaher by 0.9% during the 2nd quarter. FMR LLC now owns 19,624,350 shares of the conglomerate’s stock valued at $1,656,100,000 after buying an additional 183,183 shares during the period. Parnassus Investments CA grew its stake in shares of Danaher by 0.3% during the 3rd quarter. Parnassus Investments CA now owns 9,796,584 shares of the conglomerate’s stock valued at $840,351,000 after buying an additional 29,381 shares during the period. Finally, Flossbach Von Storch AG grew its stake in shares of Danaher by 17.2% during the 3rd quarter. Flossbach Von Storch AG now owns 6,776,921 shares of the conglomerate’s stock valued at $581,324,000 after buying an additional 994,902 shares during the period. 76.32% of the stock is owned by hedge funds and other institutional investors.
In other Danaher news, SVP Daniel Raskas sold 37,870 shares of the business’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $93.33, for a total value of $3,534,407.10. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Daniel L. Comas sold 88,184 shares of the business’s stock in a transaction on Monday, October 23rd. The stock was sold at an average price of $91.02, for a total transaction of $8,026,507.68. Following the completion of the transaction, the chief financial officer now owns 227,816 shares in the company, valued at approximately $20,735,812.32. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 273,810 shares of company stock valued at $25,218,813. 12.20% of the stock is owned by corporate insiders.
Shares of Danaher Co. (DHR) opened at $94.00 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.00 and a debt-to-equity ratio of 0.42. Danaher Co. has a 12-month low of $77.66 and a 12-month high of $94.82. The firm has a market cap of $64,586.94, a price-to-earnings ratio of 23.87, a P/E/G ratio of 2.21 and a beta of 1.02.
Danaher (NYSE:DHR) last announced its quarterly earnings results on Thursday, October 19th. The conglomerate reported $1.00 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.05. Danaher had a net margin of 13.36% and a return on equity of 11.29%. The firm had revenue of $4.53 billion during the quarter, compared to analysts’ expectations of $4.47 billion. During the same period in the prior year, the company earned $0.87 EPS. The firm’s revenue was up 9.6% on a year-over-year basis. analysts anticipate that Danaher Co. will post 3.99 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be given a dividend of $0.14 per share. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $0.56 dividend on an annualized basis and a yield of 0.60%. Danaher’s dividend payout ratio (DPR) is 16.52%.
Several analysts have recently issued reports on the stock. Citigroup boosted their price objective on shares of Danaher to $107.00 and gave the company a “buy” rating in a research note on Friday. Robert W. Baird boosted their price objective on shares of Danaher from $87.00 to $97.00 and gave the company an “outperform” rating in a research note on Friday, October 20th. Credit Suisse Group boosted their price objective on shares of Danaher from $93.00 to $96.00 and gave the company an “outperform” rating in a research note on Friday, October 20th. Morgan Stanley boosted their price objective on shares of Danaher from $95.00 to $98.00 and gave the company an “overweight” rating in a research note on Friday, October 20th. Finally, Zacks Investment Research raised shares of Danaher from a “hold” rating to a “buy” rating and set a $97.00 price objective for the company in a research note on Thursday, October 5th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $94.05.
WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/danaher-co-dhr-holdings-increased-by-parametric-portfolio-associates-llc/1767513.html.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with Analyst Ratings Network's FREE daily email newsletter.